CRISPR Patent Landscape Sample-2017-01

CRISPR Patent Landscape - SAMPLE ©2014-2017 IPStudies SARL

CRISPRPATENTLANDSCAPEJanuary2017

Intangibleassets deserve closer scrutiny

CRISPR Patent Landscape - SAMPLE ©2014-2017

Copyright

• Unless otherwise specified, all content included on this document, such astext, graphics, logos, button icons, images, audio and video clips, digitaldownloads, data compilations, and software, including but not limited toIPStudies surveys, is the property of IPStudies SARL and protected byinternational copyright laws.

• You agree not to copy, reproduce, duplicate, sell, resell, or exploit for anycommercial purposes, any portion of this content.

• You may not re-use and/or extract part of this content outside of your legalentity, institutional or corporate environment without IPStudies’s expressconsent in writing.

2


Ourteam

3

CorinneLEBUHAN,PhDICTExpertIPStrategy&Management

• FundedIPStudiesin2010tohelpSwiss&EUhigh-techSMEsdevelopandexecutetheirIPvaluationplansusingthelatestpatentanalyticstoolsandtrends

• 15yearsexperienceinIPstrategyandmanagement– formerVPKnowledgeManagementofNagravision-Kudelski Group,inchargewithpatents(200families),standards,R&Dcollaborations,licensingandtechnicalpublicationsportfolios

• TeachesinternationallicensingpracticesandIPstrategyatIEEPI–EUHorizon2020expertonInnovationinSMEs2013-2015

• ICTTechnologyExpertforvariouslicensingfacilitatorsandaggregatorsinFrance,GermanyandtheUS

• Universitypostgraduateinmanagementofinnovationandintellectualproperty(UniversityofStrasbourg,2008),PhDinCommunicationsScience(EPFL,1998),MsC inElectricalEngineering(INSARennes,1994)

• ExperiencedwithPatbase,EPO/RegisterPlus,USPTO/PAIR

• InternationalnetworkofIPpractitionersandlicensingmanagers-MemberLES,IEEE,AROPI,AAIEEPI

FabienPALAZZOLI,PhDLifeSciencesExpertPatentAnalysis&Landscapes

• JoinedIPStudies in2013todeveloptheIPanalyticsofferinginlifesciences&biotechnology

• 9+yearsexperienceintechnologytransfers,patentmapping/landscapingandFTO-drivenresearchintelligencefortheFrenchpublicsectorandbiotechSMEs- formerIPanalyticssalesmanagerforFISTSA,theCNRStechnologytransferoffice

• Author/co-authorof18scientificandtechnicalpublications/communications,aswellasonebookchapter

• Lifesciencespatentanalystforvariousbiotech/medtech SMEsinSwitzerlandandinEurope

• PhDinLifeSciences(Exploitationofpatentinformationinapublicresearchlaboratory:identificationoftechnologicalnichesinbioproduction andgenetherapy,UniversityofTours,2011),MsC inBiotechnologyandLaw(UniversityofTours,2007)

• ExperiencedwithOrbit,Patbase,Intellixir,patentofficesdatabases

• Internationalnetworkofpatentinformationanalysts


Tableofcontents

4

• Methodology• OveralltrendsoftheCRISPRpatentdatabase

• Temporaldistributionofpatentfilings(2002-2016)• Temporaldistributionofpatentfilingsbytypeofplayers(2002-2016)• Worldmapofpriorityfilings• Temporaldistributionofpriorityfilings(2002-2016)• Worldmapofpatentextensions• Mainpatentapplicants/assignees• Temporaldistributionoffilingsofapplicants/assignees• Co-filingsbetweenapplicants/assignees

• BreakdownoftheCRISPRpatentdatabase• BreakdownbyClaimcoverageofpatentfamilies

• Breakdownofthepatentportfolio• Temporaldistributionoffilings• Positioningofapplicants/assignees

• BreakdownbyComponents• Breakdownofthepatentportfolio• Temporaldistributionoffilings• Positioningoftheapplicants/assignees

• BreakdownbyChimericproteins• Breakdownofthepatentportfolio• Temporaldistributionoffilings• Positioningofapplicants/assignees

• Mainforwardcitedpatentfamilies• Appendices– licensingannouncements,affiliationmappingofplayerspresentinthepatentlandscape


Temporaldistributionofpatentfilingsbytypeofplayers(2002-2016)

Ø 707 filings by institutional applicants/assignees (61.7%),Ø 358 filings by industrial applicants/assignees (31.2%),Ø 48 filings by individual inventors (4.2%),Ø 33 co-filings between industrial applicants/assignees and institutional applicants/assignees (2.9%).Ø The years 2015 and 2016 are not complete due to the delay of publication of 18 months in most jurisdictions.

1146patentfamilies


Mainpatentapplicants/assignees (≥7patentfamilies)

Institutional applicant/assignee

Industrial applicant/assignee

Ø Affiliates & subsidiaries have been gathered under their parent company (Danisco with DuPont…). Co-filings arecounted for each co-owner: a patent application co-filed between the MIT, the Harvard University and theBroad Institute is counted once for each applicant.

Ø The patent portfolio of DuPont comprises historical patent families on CRISPR sequences dealing with the typingof bacterial strains, cultures with improved phage resistance and applications for preparing food.


Co-filingsbetweenapplicants/assignees

7

Ø The co-filing map shows the co-filings between applicants/assignees. The same type of link can be found whenan assignment occurred between two players, giving the historical applicants as well as the new owners.

Number ofpatentfamiliesintheportfolio

Co-filing(s)betweenthetwo applicants


Licensor Scope Licensee Date

Toolgen

Worldwidelicense&sublicensesrightsforresearchapplicationsincludingthedevelopmentandsaleofreagents,celllines,andanimalmodels,aswellasrightsforhighthroughputscreening,diagnostics,andbioproduction.ToolGen retainsitsrightsinbroadareasincludinghighthroughputscreening,diagnostics,bioproduction,plantbiotechnologyandgene/celltherapy.

ThermoFisher Scientific 2015/03

DuPont

Thecross-licenseenablesCariboutodevelopandutilizeCRISPR-Castechnologyforproductdevelopmentinmultiplefieldsincludinghumanandanimaltherapeutics,diagnostics,industrialbiotechnology,researchtools,andcertainagriculturesegments.TheDuPontlicensetoCaribouincludesrightstotheCas9-mediatedgenomeeditingintellectualpropertyownedbyVilniusUniversityandexclusivelylicensedtoDuPont.

CaribouBiosciences 2015/10

CaribouBiosciences

Multi-facetedagreementincludesthecross-licensingofkeyintellectualproperty,aresearchcollaboration,andfinancialinvestmentsbyDuPontinCaribou,adeveloperofCRISPR-Castechnologies.

DuPont 2015/10

CrisprTherapeutics

$105millionupfront—$75millionincash,$30millionequityinvestment- futuredevelopment,regulatoryandsalesmilestonesofupto$420millionforeachofuptosixCRISPR-Cas9-basedtreatmentsforwhichVertexhasagreedtolicenseexclusivedevelopmentrights.Royaltiesonfuturesales.

Vertex 2015/10

ERSGenomicsNon-exclusivelylicensedpatentsrelatedtoCRISPR-Cas9genome-editingtechnologytoRegeneronPharmaceuticalsforuseindrugdiscoveryanddevelopment

Regeneron 2015/11

8

Licenseannouncements– SAMPLEPAGE(4)


BreakdownoftheCRISPRpatentdatabase(1)

• Genomeediting

• Transcriptional-epigeneticregulation

• Otherapplication

• Therapeutics-Diagnostics

• Bioproduction

• Drugscreening

• Modifiedcell

• Modifiedanimal

• Modifiedplant

Applications

• Humancell-subjet

• Mammaliancell-organism

• Otheranimalcell-organism

• Plantcell-organism

• Fungi-algae-yeast

• Eukaryoticcell-organism

• Prokaryoticcell

• Otherorganism

• Undefinedcell-organism

Cells/Organisms

• Nuclease

• ZFNuclease-ZFP

• Meganuclease

• TALENuclease-TALEP

• gRNA-guidesequence

• CRISPR-associatedprotein

• CRISPR-Cas system

• Otherchimericprotein

• Vector-Delivery

• CRISPRsequence

‘Moleculartools’

‘CLAIMCOVERAGE’OFPATENTFAMILIES

The1146patentfamilies havebeenmanually reviewed andclassified

Ø A patent family can be classified in several categories (e.g. ‘Genome Editing’ and ‘Therapeutic application’and ‘Human cell-subject’ and ‘CRISPR-Cas system’…).


BreakdownoftheCRISPRpatentdatabase(2)

COMPONENTS CHIMERICPROTEINS

Chimericnucleases

• Undefinednuclease

• ZFNuclease

• Meganuclease

• TALENuclease

• RNA-GuidedNuclease

• Otherchimericnuclease

Otherchimericproteins

The1146patentfamilies havebeenmanually reviewed andclassified

• CRISPR-associatedprotein

• MutatedCas - nickase

• dCas

• Cas9

• mutatedCas9- nickase

• dCas9

• OtherCas

• OthermutatedCas

• Cpf1

• gRNA

• sgRNA-chiRNA

• crRNA

• tracrRNA

Ø A patent family can be classified in several categories (e.g. ‘Genome Editing’ and ‘Therapeutic application’and ‘Human cell-subject’ and ‘CRISPR-Cas system’…).

• Nuclease-Nickase

• Meganuclease

• Integrase

• Recombinase

• Repressor-Activator

• Acetyltransferase

• Deacetylase

• Methyltransferase

• Demethylase

• Kinase

• Othercatalyticdomain

• Undefinedcatalyticdomain

©2014-2017Copy only for COMPANY CORP

BreakdownbyClaimcoverageofpatentfamiliesBreakdownofthepatentportfolio

11

Applications Cell /Organism ‘Covered molecular tools’


BreakdownbyComponentsBreakdownofthepatentportfolio

12


BreakdownbyChimericproteinsBreakdownofthepatentportfolio

13

Nucleases including chimeric nucleases Other chimeric proteins


Furtheranalyticsforyourspecificneedswiththeonlinedatabase

• Zoomonpatentportfoliosofspecificapplicants

• Zoomonpatentsfiledinacountry/region(US,EP,CN…),withinatimeperiod

• Zoomonpatentscoveringanapplication,adedicatedtechnology,aspecificationorafunctionalsubset

• Linktoonlinepatentofficeregisterstoreviewlatestlegalstatus

14


Accesstotheinteractive“navigate,zoom,clickandshowpatent”database

15

4

1

2

3


Order

16

This is only a sample report with partial data. Our fulloffer includes:• ananalysisofthepatentlandscape,covering1146patentfamilies,worldwide• asynthesisofIPstrategyfindings,tovisualizekeytrendsintermsofpatentapplicants,collaborationnetworks,competitortechnologypositioning,keyinventorsandR&Dwhitespacesoutofthelandscape• anon-lineaccesstothe1146patentfamiliesset,soyoucanvisualize,navigate,focusandextractthemostrelevantpatentdataaccordingtoyourspecificneeds.

[email protected]+41797875746

Documents

CRISPR Patent Landscape Sample-2017-01